Roche withdraws Tecentriq combo application in firstline renal cell carcinoma httpbit.ly2TpG1f1Â pharma cancerpic.twitter.comE4BxQVdlP6
Roche withdraws Tecentriq combo application in first-line renal cell carcinoma http://bit.ly/2TpG1f1 #pharma #cancerpic.twitter.com/E4BxQVdlP6
More From BioPortfolio on "Roche withdraws Tecentriq combo application in first-line renal cell carcinoma http://bit.ly/2TpG1f1 #pharma #cancerpic.twitter.com/E4BxQVdlP6"